Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4591183 | 0.95 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL4576814 | 0.95 | CYP1A2 (0.57) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL7094816 | 0.93 | CYP3A4 (0.52) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL4590530 | 0.92 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL4590534 | 0.92 | CYP1A2 (0.55) | CYP1A2CYP3A4CYP2C9HPGDOPRM1 | |
| SCHEMBL4576023 | 0.91 | CYP3A4 (0.58) | CYP1A2CYP3A4OPRM1OPRD1OPRK1 | |
| SCHEMBL5143861 | 0.91 | CYP3A4 (0.58) | CYP1A2CYP3A4OPRM1OPRD1OPRK1 | |
| SCHEMBL4591634 | 0.88 | CYP3A4 (0.64) | CYP1A2CYP3A4OPRM1OPRD1OPRK1 | |
| SCHEMBL4577251 | 0.88 | CYP3A4 (0.64) | CYP1A2CYP3A4OPRM1OPRD1OPRK1 | |
| SCHEMBL5143548 | 0.88 | CYP3A4 (0.64) | CYP1A2CYP3A4OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053326-A9 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | CHANG KWEN-JEN (US) | 2013-02-28 | — | — | US | disclosed |
| US-20030186872-A1 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | DMK PHARMACEUTICALS CORPORATION | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186872-A1 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | OPRD1, OPRK1, OPRM1 | CYP1A2 656/4885CYP3A4 804/4885CYP2C9 1547/4885 |
| US-20130053326-A9 | Method of treating sexual dysfunctions with delta opioid receptor agonist compounds | OPRD1, OPRK1, OPRM1 | CYP1A2 656/4885CYP3A4 804/4885CYP2C9 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.